SESSION TOPICS

• Preclinical & Early Development to Reduce Attrition
• Biomarkers & Pharmacogenomics:
  Early Phase Development Acceleration
• Proof-of-Concept: Science to Strategy
• Innovative & Adaptive Clinical Trial Design
• Case Studies

FEATURED SPEAKERS

Walter Janssens, Ph.D., Senior Preclinical Assessor, Preauthorisation, Coordinator Early Phase Development, Federal Agency for Medicines and Health Products

Chris H. Takimoto, M.D., Ph.D., Senior Director, Translational Medicine, Ortho Biotech Oncology R&D/Centocor R&D, Inc.

Coreen Oei, Ph.D., Vice President, Scientific & Clinical Operations, GlaxoSmithKline

Joseph C. Fleishaker, Ph.D., FAAPS, FCP, VP, PGRD, St. Louis Laboratories, Clinical Research, Pfizer Inc.

Thierry Sornasse, Ph.D., Director, Translational Medicine, Biomarker Integration, Elan Pharmaceuticals, Inc.

Martin Wehling, M.D., Managing Director, Institute for Experimental and Clinical Pharmacology and Toxicology, 
Director, Clinical Pharmacology Mannheim Medical Faculty, Mannheim Ruprecht-Karls-University Heidelberg

SHORT COURSE 

• Evidence Led Decision Making for Clinical Proof-of-Concepts